Choosing the optimal therapy for metastatic renal cell carcinoma: Insights from a real-world comparative study.
immune checkpoint inhibitors
metastatic renal cell carcinoma
molecular target drug
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
13 Oct 2024
13 Oct 2024
Historique:
received:
30
05
2024
accepted:
16
09
2024
medline:
14
10
2024
pubmed:
14
10
2024
entrez:
14
10
2024
Statut:
aheadofprint
Résumé
The evolution of combination therapies integrating immune checkpoint inhibitors has revolutionized the first-line treatment of metastatic renal cell carcinoma (mRCC). Although these therapies are clinically approved, direct comparisons between dual immune checkpoint inhibitors (IOIO) and immune checkpoint inhibitors combined with tyrosine kinase inhibitors (IOTKI) in clinical trials are lacking. This gap creates uncertainties in selecting the most appropriate treatment based on patient-specific factors. This study employed the inverse probability of treatment weighting (IPTW) method to analyze progression-free survival (PFS) and overall survival (OS) for patients with mRCC receiving IOIO or IOTKI treatment regimens. A total of 171 patients were analyzed after applying inclusion criteria and propensity scoring. The study found no significant differences in PFS and OS between the two treatment modalities in the IPTW cohort. However, subgroup analyses revealed that IOTKI therapy was associated with better PFS and OS for patients without bone metastases and better OS for patients with a body mass index (BMI) over 25. IOIO therapy showed better OS for patients with a BMI below 18.5. Both IOIO and IOTKI therapies were effective. Therapy selection could be better tailored to patient characteristics by including factors such as the presence of bone metastases and BMI. This study enhances understanding of how patient-specific factors interact with different treatment modalities, potentially guiding more personalized treatment decisions in clinical practice for mRCC.
Sections du résumé
BACKGROUND
BACKGROUND
The evolution of combination therapies integrating immune checkpoint inhibitors has revolutionized the first-line treatment of metastatic renal cell carcinoma (mRCC). Although these therapies are clinically approved, direct comparisons between dual immune checkpoint inhibitors (IOIO) and immune checkpoint inhibitors combined with tyrosine kinase inhibitors (IOTKI) in clinical trials are lacking. This gap creates uncertainties in selecting the most appropriate treatment based on patient-specific factors.
METHODS
METHODS
This study employed the inverse probability of treatment weighting (IPTW) method to analyze progression-free survival (PFS) and overall survival (OS) for patients with mRCC receiving IOIO or IOTKI treatment regimens.
RESULTS
RESULTS
A total of 171 patients were analyzed after applying inclusion criteria and propensity scoring. The study found no significant differences in PFS and OS between the two treatment modalities in the IPTW cohort. However, subgroup analyses revealed that IOTKI therapy was associated with better PFS and OS for patients without bone metastases and better OS for patients with a body mass index (BMI) over 25. IOIO therapy showed better OS for patients with a BMI below 18.5.
CONCLUSION
CONCLUSIONS
Both IOIO and IOTKI therapies were effective. Therapy selection could be better tailored to patient characteristics by including factors such as the presence of bone metastases and BMI. This study enhances understanding of how patient-specific factors interact with different treatment modalities, potentially guiding more personalized treatment decisions in clinical practice for mRCC.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Japanese Urological Association.
Références
Motzer RJ, Tannir NM, McDermott D, Arén Frontera O, Melichar B, Choueiri TK, et al. CheckMate 214 investigators. Nivolumab plus Ipilimumab versus sunitinib in advanced renal‐cell carcinoma. N Engl J Med. 2018;378:1277–1290.
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal‐cell carcinoma. N Engl J Med. 2019;380:1116–1127.
Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal‐cell carcinoma. N Engl J Med. 2019;380:1103–1115.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal‐cell carcinoma. N Engl J Med. 2021;384:829–841.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384:1289–1300.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Bagshaw H, Baine M, et al. NCCN guidelines® insights: kidney cancer, version 2.2024. J Natl Compr Cancer Netw. 2024;22:4–16.
Ljungberg B, Albiges L, Abu‐Ghanem Y, Bedke J, Capitanio U, Dabestani S, et al. European Association of Urology guidelines on renal cell carcinoma: The 2022 update. Eur Urol. 2022;82:399–410.
Chen DS, Mellman I. Oncology meets immunology: the cancer‐immunity cycle. Immunity. 2013;39:1–10.
Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, et al. First‐line immunotherapy‐based combinations for metastatic renal cell carcinoma: a systematic review and network meta‐analysis. Eur Urol Oncol. 2021;4:755–765.
Nocera L, Karakiewicz PI, Wenzel M, Tian Z, Shariat SF, Saad F, et al. Clinical outcomes and adverse events after first‐line treatment in metastatic renal cell carcinoma: a systematic review and network meta‐analysis. J Urol. 2022;207:16–24.
Lombardi P, Filetti M, Falcone R, di Bidino R, Iacovelli R, Ciccarese C, et al. New first‐line immunotherapy‐based combinations for metastatic renal cell carcinoma: a systematic review and network meta‐analysis. Cancer Treat Rev. 2022;106:102377.
Heng DYC, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor‐targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794–5799.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247.
Leite W. Practical propensity score methods using R. 1st ed. Thousand Oaks, CA: SAGE Publications; 2016.
Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:l5657.
Ishihara H, Omae K, Nemoto Y, Ishiyama R, Tachibana H, Nishimura K, et al. First‐line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real‐world data. Int J Clin Oncol. 2024;29:473–480.
Aeppli S, Schmaus M, Eisen T, Escudier B, Grünwald V, Larkin J, et al. First‐line treatment of metastatic clear cell renal cell carcinoma: a decision‐making analysis among experts. ESMO Open. 2021;6:100030.
Shah NJ, Sura SD, Shinde R, Shi J, Singhal P, Perini RF, et al. Real‐world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab. Urol Oncol. 2023;41:459.e1–459.e8.
Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, et al. Real‐world outcome of patients with advanced renal cell carcinoma and intermediate‐ or poor‐risk international metastatic renal cell carcinoma database consortium criteria treated by immune‐oncology combinations: differential effectiveness by risk group? Eur Urol Oncol. 2024;7:102–111.
Yoshino M, Ishihara H, Nemoto Y, Nakamura K, Nishimura K, Tachibana H, et al. Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Jpn J Clin Oncol. 2022;52:1208–1214.
Choy E, Cote GM, Michaelson MD, Wirth L, Gainor JF, Muzikansky A, et al. Phase II study of cabozantinib in patients with bone metastasis. Oncologist. 2022;27:600–606.
Ji J, Yao Y, Guan F, Luo L, Zhang G. Impact of BMI on the survival of renal cell carcinoma patients treated with targeted therapy: a systematic review and meta‐analysis. Nutr Cancer. 2023;75:1768–1782.
Choi Y, Park B, Jeong BC, Seo SI, Jeon SS, Choi HY, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical‐based cohort and meta‐analysis. Int J Cancer. 2013;132:625–634.
Ishihara H, Nishimura K, Ikeda T, Fukuda H, Yoshida K, Iizuka J, et al. Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. Urol Oncol. 2024;42:291.
Rinninella E, Cintoni M, Raoul P, Pozzo C, Strippoli A, Ponziani FR, et al. Skeletal muscle loss during multikinase inhibitors therapy: molecular pathways, clinical implications, and nutritional challenges. Nutrients. 2020;12:3101.
de Leo S, Colombo C, di Stefano M, Dubini A, Cozzi S, Persani L, et al. Body composition and leptin/ghrelin levels during lenvatinib for thyroid cancer. Eur Thyroid J. 2020;9:1–10.
Colomba E, Alves Costa Silva C, le Teuff G, Elmawieh J, Afonso D, Benchimol‐Zouari A, et al. Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma. J Cachexia Sarcopenia Muscle. 2022;13:2405–2416.
Wang SV, Jin Y, Fireman B, Gruber S, He M, Wyss R, et al. Relative performance of propensity score matching strategies for subgroup analyses. Am J Epidemiol. 2018;187:1799–1807.